Genomic Health Company Updates | Glassdoor

Company Updates

  • We are pleased to announce the publication of results of a large prospective trial validating the detection of AR-V7 biomarker using Epic Sciences AR-V7 test, commercialized in the US as Oncotype DX® AR-V7 Nucleus Detect™by Genomic Health. Press release:
    #ARV7 #JCOCCI #genomichealth

    PROPHECY Validation Trial Publication :: Epic Sciences

    New data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.


    Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes | Genomic Health, Inc.

    Back Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients worldwide since it made its first test available to patients in 2004.

  • Listen to Bret Miller discuss his experience with hashtag#Oncotype DX and how the test played an instrumental role in his hashtag#breastcancer treatment decision.

    Male Breast Cancer Survivor | Health Professional Radio

    Bret Miller, breast cancer survivor and co-founder of the Male Breast Cancer Coalition , discusses his unique story and how genomic testing helped him determine the best course of treatment for his disease. He also talks about his nonprofit organization and its mission to help spread the word that breast cancer does not discriminate.

  • Intern Poster Fair 2018

  • "Genomic Health Employees Doing Life, Changing Work"

  • “I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I received my Genomic Prostate Score.” Read more of Dan’s story: #prostatecancer

    Patient Stories | Oncotype DX GPS(TM) | Oncotype IQ®

    Dan W., a 60-year-old husband, grandfather, and attorney, was diagnosed with prostate cancer in September 2013, and was presented with the choice of surgery or radiation treatment. Alarmed by the likely side effects of incontinence and impotence, Dan began his own research and became intrigued with a third option - active surveillance, or regular and close monitoring of his disease.

  • Did you know? The Oncotype DX Breast DCIS Score test provides breast cancer information beyond traditional measures. Read more:

    About the Oncotype DX® Breast DCIS Score(TM) | Oncotype IQ®

    The first and only clinically-validated, commercially available genomic assay for patients with DCIS breast cancer.

  • There are a number of prostate cancer treatments to consider, and each type brings different benefits and risks.

  • The Oncotype DX test is a biopsy-based genomic test. While genomics and genetics may sound similar, and are related, they provide different information:

  • Did you know? DCIS affects an estimated 50,000 women in the U.S. each year, making it one of the most commonly diagnosed #breastcancer conditions.

Work at Genomic Health? Share Your Experiences

Genomic Health
  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate